TY - JOUR
T1 - Emerging Applications of Metabolomics in Clinical Pharmacology
AU - Pang, Huanhuan
AU - Jia, Wei
AU - Hu, Zeping
N1 - Funding Information:
Z.H. is supported by grants from Tsinghua-Peking Joint Center for Life Sciences, Beijing Frontier Research Center for Biological Structure, Tsinghua University (53332200517), and National Science and Technology Major Project for “Significant New Drugs Development” (2017ZX09304015). Z.H. is the recipient of Bayer Investigator Award.
Funding Information:
Z.H. is supported by grants from Tsinghua-Peking Joint Center for Life Sciences, Beijing Frontier Research Center for Biological Structure, Tsinghua University (53332200517), and National Science and Technology Major Project for ?Significant New Drugs Development? (2017ZX09304015). Z.H. is the recipient of Bayer Investigator Award. We appreciate many other excellent publications that have contributed to the metabolomics field and its applications in clinical pharmacology studies. Due to the space limitation, we regret that we were unable to include all the relevant work in this review.
Publisher Copyright:
© 2019 The Authors Clinical Pharmacology & Therapeutics © 2019 American Society for Clinical Pharmacology and Therapeutics
PY - 2019/9
Y1 - 2019/9
N2 - Metabolic disturbances have been associated with many human diseases, including cancer, diabetes, and cardiovascular disease. Metabolomics, a rapidly growing member of the –omics family, investigates cellular metabolism by quantifying metabolites on a large scale and provides a link between metabolic pathways and the upstream genome that governs them. With the advances in analytical technologies, metabolomics is becoming a powerful tool for identifying diagnostic biomarkers of diseases, elucidating the pathological mechanisms, discovering novel drug targets, predicting drug responses, interpreting the mechanisms of drug action, as well as enabling precision treatment of patients. In this review, we highlight the recent advances of technologies and methodologies in metabolomics and their applications to the field of clinical pharmacology. Recent publications from 2013 to 2018 are covered in the review, and current challenges and potential future directions in the field are also discussed.
AB - Metabolic disturbances have been associated with many human diseases, including cancer, diabetes, and cardiovascular disease. Metabolomics, a rapidly growing member of the –omics family, investigates cellular metabolism by quantifying metabolites on a large scale and provides a link between metabolic pathways and the upstream genome that governs them. With the advances in analytical technologies, metabolomics is becoming a powerful tool for identifying diagnostic biomarkers of diseases, elucidating the pathological mechanisms, discovering novel drug targets, predicting drug responses, interpreting the mechanisms of drug action, as well as enabling precision treatment of patients. In this review, we highlight the recent advances of technologies and methodologies in metabolomics and their applications to the field of clinical pharmacology. Recent publications from 2013 to 2018 are covered in the review, and current challenges and potential future directions in the field are also discussed.
UR - http://www.scopus.com/inward/record.url?scp=85069861397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069861397&partnerID=8YFLogxK
U2 - 10.1002/cpt.1538
DO - 10.1002/cpt.1538
M3 - Review article
C2 - 31173340
AN - SCOPUS:85069861397
SN - 0009-9236
VL - 106
SP - 544
EP - 556
JO - Clinical Pharmacology and Therapeutics
JF - Clinical Pharmacology and Therapeutics
IS - 3
ER -